Andexanet alfa withdrawn in Australia — what patients on apixaban need to know

What happened

On 20 May 2026, the Therapeutic Goods Administration announced that andexanet alfa — sold under the brand name Andexxa — had been removed from the Australian Register of Therapeutic Goods. Its provisional registration, granted in July 2023, lapsed because the available evidence was no longer sufficient to confirm that its benefits outweigh its risks.

Andexanet alfa was designed for one specific, high-stakes situation: a patient on apixaban (Eliquis) or rivaroxaban (Xarelto) develops a life-threatening or uncontrolled bleed. Apixaban and rivaroxaban are two of the most widely prescribed anticoagulants in Australia — used for atrial fibrillation, venous thromboembolism, and stroke prevention. Unlike warfarin, which had specific reversal agents, patients on these newer Factor Xa inhibitors had no approved reversal option in Australia until 2023.

If you or someone you know is on apixaban or rivaroxaban, the natural question is: what does this mean for me? The short answer is that your daily anticoagulation is unchanged. The fuller picture is worth understanding — because it directly affects emergency bleeding management, and because it illustrates how drug safety evidence evolves after provisional approval.

What the trial data showed

The pivotal randomised controlled trial — the ANNEXA-I study — compared andexanet alfa directly against usual care in patients with Factor Xa inhibitor-associated major bleeding. The ANNEXA-I subanalysis documented a specific problem: thrombotic events were substantially more common in the andexanet alfa group. Overall thrombosis at 30 days was recorded at 14.6% in the andexanet alfa group versus 6.9% with usual care. Thrombosis-related deaths were 2.5% versus 0.9%. Ischaemic stroke, myocardial infarction, pulmonary embolism, and deep vein thrombosis all occurred at higher rates within days of the reversal agent being given.

On the primary outcome — haemostatic effectiveness — andexanet alfa performed. The earlier ANNEXA-4 observational study (Circulation 2022) showed effective or excellent haemostasis in 82% of patients. The drug does what it is pharmacologically designed to do.

The problem lies in the mechanism. Andexanet alfa inhibits tissue factor pathway inhibitor (TFPI) — a natural anticoagulant brake that limits thrombin generation. When TFPI is suppressed, the coagulation system can tip into a pro-thrombotic state beyond what is needed to control the initial bleed. In patients who are already at elevated cardiovascular risk — which describes most people on long-term anticoagulation — that additional pro-coagulant push carries real clinical consequences.

Australian Prescriber had flagged these concerns in its review, noting that the overall mortality benefit compared with 4-factor PCC had not been clearly established. The TGA’s decision to allow the provisional registration to lapse follows that direction of evidence.

The both-and

There are two true things here, and they deserve to be held together rather than collapsed into a simple narrative.

The first: reversing anticoagulation in life-threatening haemorrhage is genuinely necessary. Patients on apixaban or rivaroxaban who develop intracranial haemorrhage, major gastrointestinal bleeding, or require urgent surgery have real clinical need. Having a targeted, pharmacologically specific reversal agent is a reasonable goal. The TGA’s provisional approval in 2023 was appropriate given what the evidence showed at the time.

The second: a reversal agent that stops bleeding by tipping the coagulation system toward clotting poses a particular risk in exactly the patients who need it most — those at highest cardiovascular risk. A near-doubling of thrombotic event rates at 30 days is not a minor signal.

The TGA made a defensible call based on the accumulated evidence. It also leaves emergency teams without a Factor Xa-specific reversal agent while an alternative fills the role.

What changes — and what doesn’t

Your daily anticoagulation is unchanged. Apixaban and rivaroxaban remain available, effective, and prescribed. The TGA decision affects the emergency reversal agent, not the medicines themselves.

In Australian hospitals, 4-factor prothrombin complex concentrate (4-factor PCC) is now the primary strategy for managing Factor Xa inhibitor-related major haemorrhage. PCC has a long track record for warfarin reversal and has been used off-label for Factor Xa inhibitor reversal for years. The available data does not demonstrate a meaningful difference in overall mortality between PCC and andexanet alfa — and PCC carries a lower apparent thrombosis risk in the comparisons to date.

If you take apixaban or rivaroxaban and have elective surgery planned, the standard pre-operative management — a holding period determined by your surgeon and GP — is unchanged. Pharmacological reversal is generally not relevant for planned surgery; the change affects unplanned emergency presentations.

If you have questions about your anticoagulation, including what happens in an emergency, that conversation is worth having with your GP.

Verdict

Verdict: yes — worth knowing about.

The stroke-prevention benefit of anticoagulation in atrial fibrillation, and the treatment benefit in venous thromboembolism, significantly outweighs the background risk of major haemorrhage — that arithmetic has not changed. What has changed is which tool the emergency team reaches for if a major bleed occurs.

This is pharmacovigilance working as designed. Provisional registration gave conditional access while the evidence matured. When that evidence raised concerns, the TGA acted. The implications for day-to-day life on anticoagulation are minimal; the implications for emergency hospital medicine are immediate and being managed.

---

Sources cited

1. TGA — Lapse of provisional registration for Andexxa (andexanet alfa), May 2026
2. ANNEXA-I — Thromboembolic events in Factor Xa inhibitor-associated intracranial haemorrhage (PMC 2025)
3. Connolly et al — Full Study Report of Andexanet Alfa for Factor Xa inhibitor major bleeding (Circulation 2022)
4. Australian Prescriber — Andexanet alfa for reversal of Factor Xa inhibitor anticoagulation
5. TGA — Andexxa product page